AC
ACH.US Accendra Health Inc
- Market cap
- USD 11.2M
- P/E
- -
- P/B
- 1.07x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACH.US undervalued?
Graham numberThe Graham number of Accendra Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Accendra Health Inc fundamental analysis
No fundamental analysis for Accendra Health Inc yet.
Accendra Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Accendra Health Inc
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also su…
Full company profileAccendra Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Accendra Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.72B | 9.32B | 9.42B | 9.21B | 8.48B | 9.79B | 9.96B | 10.3B | 10.7B | 2.76B | 2.46B |
| Gross Profit | 1.19B | 1.17B | 1.07B | 1.13B | 1.28B | 1.51B | 1.83B | 2.13B | 2.22B | 1.29B | 1.07B |
| Operating Income | 200M | 89.3M | -352M | 73.2M | 204M | 368M | 143M | 105M | -208M | 222M | -14.7M |
| EBITDA | 280M | 209M | -273M | 216M | 334M | 415M | 368M | 391M | 51.2M | 220M | 122M |
| Net Income | 109M | 72.8M | -437M | -62.4M | 29.9M | 222M | 22.4M | -41.3M | -363M | -1.10B | -154M |
| EPS | 1.78 | 1.21 | -7.28 | -1.03 | 0.47 | 2.94 | 0.29 | -0.54 | -4.73 | -14 | -2.00 |
| Balance Sheet | |||||||||||
| Total Assets | 2.72B | 3.38B | 3.77B | 3.64B | 3.34B | 3.54B | 5.39B | 5.09B | 4.66B | 2.45B | 2.08B |
| Total Liabilities | 1.76B | 2.36B | 3.26B | 3.18B | 2.62B | 2.60B | 4.44B | 4.17B | 4.09B | 2.91B | 2.65B |
| Shareholders' Equity | 960M | 1.02B | 518M | 462M | 712M | 939M | 946M | 924M | 565M | -461M | -568M |
| Cash & Short-term Investments | 185M | 105M | 66.3M | 67.0M | 118M | 55.7M | 69.5M | 243M | 49.4M | 282M | 26.6M |
| Total Debt | 565M | 901M | 1.65B | 1.71B | 1.14B | 1.15B | 2.79B | 2.41B | 2.14B | 2.23B | 1.85B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 187M | 56.8M | 116M | 166M | 339M | 124M | 325M | 741M | 161M | -102M | -125M |
| Capital Expenditure | 30.1M | 50.7M | 65.7M | 52.2M | 59.2M | 49.7M | 167M | 208M | 228M | 201M | 174M |
| Free Cash Flow | 157M | 6.04M | 49.9M | 114M | 280M | 74.5M | 158M | 533M | -66.7M | -303M | -174M |
| Ratios | |||||||||||
| ROE | 11.3% | 7.2% | -84.3% | -13.5% | 4.2% | 23.6% | 2.4% | -4.5% | -64.2% | - | - |
| ROA | 4.0% | 2.2% | -11.6% | -1.7% | 0.9% | 6.3% | 0.4% | -0.8% | -7.8% | -44.9% | -7.4% |
| Net Profit Margin | 1.1% | 0.8% | -4.6% | -0.7% | 0.4% | 2.3% | 0.2% | -0.4% | -3.4% | -39.8% | -6.3% |
| Debt to Equity | 0.59x | 0.89x | 3.18x | 3.70x | 1.60x | 1.23x | 2.95x | 2.60x | 3.79x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Accendra Health Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 14, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 731K | 0.01 | 0.3% |
| 2020 | USD 648K | 0.01 | 2.2% |
| 2019 | USD 5.23M | 0.09 | - |
| 2018 | USD 48.2M | 0.80 | - |
| 2017 | USD 63.2M | 1.05 | 86.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Apr 1, 2010.
Who owns Accendra Health Inc
- Insiders 7.28%
- Institutions 85.03%
- Public & others 7.69%
- Shares outstanding 76.9M
- Free float 56.2M
Top funds holding ACH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.19M | 2.84% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 2.15M | 2.80% | +6,222.92% | Oct 2026 |
| iShares Russell 2000 ETF | 1.93M | 2.51% | 0.00% | Oct 2026 |
| PIMCO RAE US S Instl | 1.78M | 2.32% | +6.94% | Jun 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 1.26M | 1.64% | 0.00% | Oct 2026 |
| Invenomic Institutional | 914K | 1.19% | -33.16% | Jul 2026 |
| Fidelity Small Cap Index | 836K | 1.09% | +6.49% | Aug 2026 |
| iShares Russell 2000 Value ETF | 665K | 0.87% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap Value I | 529K | 0.69% | +9.60% | Sep 2026 |
| DFA U.S. Targeted Value I | 470K | 0.61% | 0.00% | Sep 2026 |
| Vanguard US Value Factor ETF | 427K | 0.56% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 419K | 0.54% | +1.40% | Sep 2026 |
| Schwab Fundamental US Small Company Idx | 327K | 0.43% | -27.38% | Sep 2026 |
| Fidelity Extended Market Index | 321K | 0.42% | -12.78% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 302K | 0.39% | -40.51% | Sep 2026 |
| iShares Micro-Cap ETF | 230K | 0.30% | 0.00% | Oct 2026 |
| Vanguard Strategic Equity Inv | 197K | 0.26% | -53.90% | Sep 2026 |
| Vanguard Health Care ETF | 187K | 0.24% | +0.10% | Sep 2026 |
| Schwab Small Cap Index | 177K | 0.23% | 0.00% | Sep 2026 |
| Vanguard Growth & Income Inv | 157K | 0.20% | +5.81% | Sep 2026 |
Top institutions holding ACH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Coliseum Capital Management LLC | 13.1M | 17.04% | 0.00% | Jun 2026 |
| BlackRock Inc | 5.50M | 7.16% | +5.13% | Jun 2026 |
| Bank of America Corp | 3.78M | 4.91% | +10.81% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.09M | 4.02% | -5.92% | Jun 2026 |
| D. E. Shaw & Co LP | 3.08M | 4.01% | -6.95% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.89M | 3.76% | -20.56% | Jun 2026 |
| Invenomic Capital Management, LP | 2.81M | 3.66% | -16.52% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.58M | 3.36% | +46.65% | Jun 2026 |
| Paradigm Capital Management, Inc. | 2.54M | 3.30% | +42.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.03M | 2.64% | -23.39% | Jun 2026 |
| Dana Investment Advisors Inc | 1.94M | 2.53% | +30.94% | Jun 2026 |
| Geode Capital Management, LLC | 1.87M | 2.44% | +2.03% | Jun 2026 |
| State Street Corp | 1.60M | 2.08% | -1.77% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 1.29M | 1.68% | -6.66% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.15M | 1.49% | -30.00% | Sep 2026 |
| AQR Capital Management LLC | 1.07M | 1.39% | +45.77% | Jun 2026 |
| The Goldman Sachs Group Inc | 855K | 1.11% | -9.18% | Jun 2026 |
| Acadian Asset Management LLC | 820K | 1.07% | -9.59% | Jun 2026 |
| Two Sigma Investments LLC | 719K | 0.93% | -40.18% | Jun 2026 |
| Northern Trust Corp | 582K | 0.76% | -3.19% | Jun 2026 |
Accendra Health Inc company profile
- Company name
- Accendra Health Inc
- Ticker
- ACH.US
- Exchange
- USA Stocks
- Listed since
- Dec 16, 1988
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 6,500
- Fiscal year end
- December
- Address
- 4435 Waterfront Drive, Glen Allen, VA, United States, 23060
- Phone
- (804) 277-4304
- Website
- accendrahealth.com
About Accendra Health Inc
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.
Accendra Health Inc management
10- Mr. Kenneth Gardner-SmithPresident, CEO & Director · born 1981
- Mr. Jonathan A. LeonExecutive VP, CFO & Corporate Treasurer · born 1967
- Mr. Heath H. GallowayExecutive VP, General Counsel & Corporate Secretary · born 1977
- Mr. Perry A. BernocchiStrategic Advisor to the CEO · born 1959
- Mr. Nicholas PiecoraSenior VP & Chief Information Officer
- Will ParrishVP of Strategy, Corporate Development, & IR
- Ms. Carrie ChildressExecutive VP & Chief Marketing Officer
- Mr. Dirk BensonChief Commercial Officer
- Mr. Colin BainChief Products Officer
- Ms. Agnes AnsayVP & Chief Procurement Officer